Abstract:Rengui Zhou, 1 Lei Song, 1 Wenwen Zhang, 1 Lin Shao, 2 Xi Li, 2 Xiangyong Li 1 1 Department of Hematology and Oncology, The 904 Hospital of the PLA (Chinese People's Liberation Army), Wuxi, People's Republic of China; 2 Burning Rock Biotech, Guangzhou, Guangdong, People's Republic of China Correspondence: Xiangyong Li Department of Hematology and Oncology, The 904 Hospital of The PLA (Chinese People's Liberation Army), North XingYuan Road NO.101, Wuxi, Jiangsu, 214044, People's Republic of China Email The emergence of epidermal growth factor receptor ( EGFR ) exon 20 p.C797S is one of the major resistance mechanisms for osimertinib. However, there are no standard of care for non-small cell lung cancer (NSCLC) patients after acquiring EGFR C797S currently, which brings significant challenges to post-osimertinib clinical management. In the present study, we described a 52-year-old female patient with EGFR -mutated stage IV lung adenocarcinoma, who achieved a partial response (PR) to the treatment of gefitinib and osimertinib after acquiring EGFR exon 20 p.T790M-trans-C797S at osimertinib failure. After progression on the combinatorial treatment, allelic configuration shifted to T790M-cis-C797S. The patient subsequently received a regimen of osimertinib and anlotinib combined with chemotherapy, followed by osimertinib and anlotinib maintenance treatment, and achieved a PR lasting for 9 months. At disease progression, concomitant T790M-C797S mutations both in trans and cis were identified. A combination of chemo- and anti-angiogenic therapies was administrated for two cycles and then discontinued because of the poor physical condition of the patient. She passed away soon with an overall survival of 39 months and a post-osimertinib progression survival of 20 months. Our study provides the first clinical evidence that the osimertinib and anlotinib-based regimen may be an effective therapy in overcoming resistance mediated by T790M-cis-C797S. Our case also highlights the importance of dynamically monitoring the mutation status after osimertinib failure, which may provide patients with increased opportunities for targeted therapy and improve post-osimertinib progression survivals. Keywords: EGFR TKI, EGFR T790M, EGFR C797S, NSCLC, osimertinib, anlotinib Most epidermal growth factor receptor ( EGFR )-mutant non-small cell lung cancer (NSCLC) patients with initial responsiveness to EGFR tyrosine kinase inhibitors (TKIs) will inevitably acquire drug resistance. Secondary EGFR exon20 p.T790M (T790M) is the most common mechanism mediating the resistance to first- and second-generation TKIs. 1 The third-generation EGFR TKI osimertinib selectively targets both activating EGFR mutations and T790M. Despite its robust clinical efficacy and promising survival advantages, osimertinib-treated patients ultimately develop secondary resistance with the emergence of EGFR exon20 p.C797S (C797S) in cis or trans with T790M as the major mechanism. 2 In cis and in trans configuration refers to that C797S is present on the same and different EGFR allele as T790M, respectively. 3 Unfortunately, there is no standard of care for EGFR -mutant NSCLC patients after acquiring C797S, which brings significant challenges to post-osimertinib clinical management. T790M-trans-C797S, which occurs in ~10% of C797S cases, has been reported to respond to the combination of first and third-generation EGFR-TKIs. 4 Whereas, T790M-cis-C797S, the more frequent allelic configuration accounting for ~80% of C797S cases, 5 lacks effective targeted therapy. Here, we reported a patient with stage IV lung adenocarcinoma, who achieved a partial response (PR) to the treatment of gefitinib combined with osimertinib after acquiring T790M-trans-C797S at osimertinib failure. After progression on combinatorial treatment, allelic configuration shifted to T790M-cis-C797S. The patient subsequently received a regimen of osimertinib and anlotinib combined with chemotherapy and achieved a sustained response of 9 months. The patient's diagnostic and treatment history was summarized in Figure 1A . The 52-year-old female presented to our hospital in June 2017, with coughing of phlegm for 1 month and a PS score of 1. Chest computed tomography (CT) scan revealed consolidation in right lower lung accompanied with right pleural effusion and scattered miliary opacities on both lungs ( Figure 1B ). The patient subsequently underwent a bronchofibroscopy and was diagnosed with stage IV (cTxNxM1) ade -Abstract Truncated-

Osimertinib in Combination with Bevacizumab in EGFR-Mutated NSCLC with Leptomeningeal Metastases

Osimertinib combined with bevacizumab as the first‐line treatment in non‐small cell lung cancer patients with brain metastasis harboring epidermal growth factor receptor mutations

Safety and Efficacy of Osimertinib Plus Bevacizumab As First-Line Treatment in EGFRmutated NSCLC with Brain Metastasis Instructed by Dynamic Monitoring Circulating Tumor DNA of Paired Cerebrospinal Fluid and Plasma

Complete remission in leptomeningeal metastasis of NSCLC with rare EGFR-SEPT14 fusion treated with osimertinib combined with intrathecal chemotherapy with pemetrexed

Case Report: Osimertinib Followed by Osimertinib Plus Bevacizumab, Personalized Treatment Strategy for a Lung Cancer Patient With a Novel EGFR Exon 20 Insertion D770_N771insGT and Multiple Brain Metastases

Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) combined with bevacizumab for advanced non-squamous non-small-cell lung cancer patients with gradual progression on EGFR-TKI treatment A cohort study

Efficacy and safety of osimertinib plus bevacizumab versus osimertinib alone for advanced non-small-cell lung cancer with EGFR mutations: A meta-analysis of randomized controlled trials

Clinical Management in NSCLC Patients With EGFR Mutation After Osimertinib Progression With Unknown Resistance Mechanisms

Treatment Response to Osimertinib in EGFR-Mutated Leptomeningeal Metastases from Non-Small Cell Lung Cancer: A Case Series.

Double-dose osimertinib combined with intrathecal injection of pemetrexed improves the efficacy of EGFR-mutant non-small cell lung cancer and leptomeningeal metastasis: case report and literature review

Comparison of osimertinib plus bevacizumab against osimertinib alone in NSCLC harboring EGFR mutations: a systematic review and meta-analysis

Non-small cell lung cancer leptomeningeal metastases treated with intrathecal therapy plus osimertinib and temozolomide and whole-brain radiation therapy: a case report

Ott_a_199452 7785..7790

Combination of Osimertinib and Anlotinib May Overcome the Resistance Mediated by in cis EGFR T790M-C797S in NSCLC: A Case Report

Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial

Afatinib overcoming resistance to icotinib and osimertinib in NSCLC with leptomeningeal metastasis in patients with acquired EGFR L858R/T790M or L858R/S768I mutations: Two case reports

Survival benefit of anlotinib in T790M‐positive non‐small‐cell lung cancer patients with acquired osimertinib resistance: A multicenter retrospective study and exploratory in vitro study

Genomic profiling of cerebrospinal fluid ctDNA to characterize molecular features and monitor intracranial responses of patients with osimertinib-resistant non-small cell lung cancer with leptomeningeal metastases.

Genotyping of Cerebrospinal Fluid Associated With Osimertinib Response and Resistance for Leptomeningeal Metastases in EGFR-Mutated NSCLC

Effect of bevacizumab plus double dose icotinib on advanced non-small cell lung cancer with EGFR L858R mutation.

Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies